Literature DB >> 14610722

Borderline personality and psychotropic medication prescription in an outpatient psychiatry clinic.

Randy A Sansone1, Dorota Rytwinski, George A Gaither.   

Abstract

Borderline personality is a complex disorder and pharmacological intervention is typically focused on target symptoms. Previous studies indicate that patients with borderline personality disorder (BPD) are prescribed a greater number of psychotropic medications than those without BPD. However, these studies were self-report in design and/or preceded the use of newer psychotropic medications such as selective serotonin reuptake inhibitors (SSRIs). In this study, we explored among 280 psychiatric outpatients the relationships between an axis II diagnosis of BPD and the number of axis I diagnoses, psychotropic medications, and psychotherapy sessions. Compared to those with other types of personality disorders (n=128) or no personality disorder at all (n=91), those with BPD (n=61) were diagnosed with significantly more axis I disorders, prescribed significantly more psychotropic medications, and attended significantly more psychotherapy sessions. These findings suggest that: (1) BPD patients will probably be prescribed more psychotropic medications than other psychiatric outpatients, and (2) in addition to psychotropic medication prescription, there may be additional variables (e.g., psychotherapy sessions) that make a meaningful contribution to the overall healthcare utilization among those with BPD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14610722     DOI: 10.1016/S0010-440X(03)00147-0

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  10 in total

1.  Borderline personality: a primary care context.

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Psychiatry (Edgmont)       Date:  2004-09

Review 2.  Pharmacotherapy for borderline personality disorder--current evidence and recent trends.

Authors:  Jutta M Stoffers; Klaus Lieb
Journal:  Curr Psychiatry Rep       Date:  2015-01       Impact factor: 5.285

Review 3.  Borderline personality disorder: considerations for inclusion in the Massachusetts parity list of "biologically-based" disorders.

Authors:  Mary Ellen Foti; Jeffrey Geller; Laura S Guy; John G Gunderson; Brian A Palmer; Lisa M Smith
Journal:  Psychiatr Q       Date:  2011-06

4.  The State of Overmedication in Borderline Personality Disorder: Interpersonal and Structural Factors.

Authors:  Rosa Shapiro-Thompson; Sarah K Fineberg
Journal:  Curr Treat Options Psychiatry       Date:  2022-03-04

5.  The relationship between borderline personality symptomatology and somatic preoccupation among internal medicine outpatients.

Authors:  Randy A Sansone; Nighat A Tahir; Victoria R Buckner; Michael W Wiederman
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

6.  Use of escitalopram during pregnancy: navigating towards international guidelines and the real world.

Authors:  Salvatore Gentile
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

7.  Borderline personality disorder: are proliferative symptoms characteristic?

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Psychiatry (Edgmont)       Date:  2008-08

8.  Relationship between maladaptive cognitions about sleep and recovery in patients with borderline personality disorder.

Authors:  David T Plante; Frances R Frankenburg; Garrett M Fitzmaurice; Mary C Zanarini
Journal:  Psychiatry Res       Date:  2013-08-23       Impact factor: 3.222

9.  Rest, Reactivity, and Recovery: A Psychophysiological Assessment of Borderline Personality Disorder.

Authors:  David Eddie; Marsha E Bates; Evgeny G Vaschillo; Paul M Lehrer; Michelle Retkwa; Michael Miuccio
Journal:  Front Psychiatry       Date:  2018-10-16       Impact factor: 4.157

10.  Psychotropic medication use in hospitalized patients with borderline personality disorder.

Authors:  Karen E Moeller; Amad Din; Macey Wolfe; Grant Holmes
Journal:  Ment Health Clin       Date:  2016-03-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.